The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM¿) paradigm: Conceptual framework and therapeutic potential Academic Article in Scopus uri icon

abstract

  • In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM¿) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM¿ agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM¿ agonist safely reduces residual cardiovascular risk. © 2019 The Author(s).

publication date

  • June 4, 2019